The study of efficacy of lenvatinib in patients with hepatocellular carcinoma(HCC): Multicenter analysis.
- Conditions
- Hepatocellular carcinoma
- Registration Number
- JPRN-UMIN000037054
- Lead Sponsor
- Yokohama City University Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 250
Not provided
1)Clinically significant ascites (refractory ascites requiring drainage) 2)Esophageal varices with the potential to bleed 4)Brain tumor 5)On dialysis 6)Gastrointestinal hemorrhage during past month 7)Active multiple cancer 8)Any of the following concurrent diseases: Grade 3 or greater arrhythmia or poorly controlled hypertension according to the JCOG/JSCO Japanese translation of the NCI Common Terminology Criteria for Adverse Events v 4.0 (CTCAE v 4.0) 9)Orally taking an herbal medicine approved for the treatment of cancer (e.g., shosaikoto) 10)Human immunodeficiency virus (HIV) or acquired immune deficiency syndrome (AIDS) related disease 11) Pregnant or nursing 12) Otherwise found ineligible as a subject by the researcher
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method